|
GB9828511D0
(en)
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
|
US6906067B2
(en)
|
1999-12-28 |
2005-06-14 |
Bristol-Myers Squibb Company |
N-heterocyclic inhibitors of TNF-α expression
|
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
|
DZ3401A1
(fr)
|
2000-07-19 |
2002-01-24 |
Warner Lambert Co |
Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
|
|
GB0021726D0
(en)
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
|
EP1317450B1
(en)
|
2000-09-15 |
2006-11-22 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
AU2002216650A1
(en)
|
2000-10-31 |
2002-05-15 |
Lynn Bonham |
Triazine derivatives as lpaat-b inhibitors and uses thereof
|
|
US6670357B2
(en)
|
2000-11-17 |
2003-12-30 |
Bristol-Myers Squibb Company |
Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
|
|
US6867300B2
(en)
|
2000-11-17 |
2005-03-15 |
Bristol-Myers Squibb Company |
Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
|
|
IL156315A0
(en)
|
2000-12-07 |
2004-01-04 |
Cv Therapeutics Inc |
Abca-1 elevating compounds
|
|
NZ526472A
(en)
|
2000-12-21 |
2004-04-30 |
Vertex Pharma |
Pyrazole compounds useful as protein kinase inhibitors
|
|
EP1343782B1
(en)
|
2000-12-21 |
2009-05-06 |
SmithKline Beecham Corporation |
Pyrimidineamines as angiogenesis modulators
|
|
BR0206844A
(pt)
*
|
2001-01-31 |
2005-07-12 |
Synaptic Pharma Corp |
Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos
|
|
GB0103926D0
(en)
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
|
US6887873B2
(en)
|
2001-03-23 |
2005-05-03 |
Aventis Pharma S.A. |
Triazine derivatives and their application as antitelomerase agents
|
|
KR100798579B1
(ko)
*
|
2001-03-31 |
2008-01-28 |
동화약품공업주식회사 |
신규의 메톡시-1,3,5-트리아진 유도체 및 그를 포함하는약학적 조성물
|
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
|
JP2005500294A
(ja)
*
|
2001-06-19 |
2005-01-06 |
ブリストル−マイヤーズ スクイブ カンパニー |
ホスホジエステラーゼ７に対するピリミジン阻害剤
|
|
CA2451125A1
(en)
*
|
2001-06-26 |
2003-01-09 |
Bristol-Myers Squibb Company |
N-heterocyclic inhibitors of tnf-alpha expression
|
|
US20030139435A1
(en)
|
2001-06-26 |
2003-07-24 |
Gulzar Ahmed |
N-heterocyclic inhibitors of TNF-alpha expression
|
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
|
US7112587B2
(en)
|
2001-09-21 |
2006-09-26 |
Reddy Us Therapeutics, Inc. |
Methods and compositions of novel triazine compounds
|
|
US7173032B2
(en)
|
2001-09-21 |
2007-02-06 |
Reddy Us Therapeutics, Inc. |
Methods and compositions of novel triazine compounds
|
|
RS34004A
(sr)
*
|
2001-09-21 |
2006-10-27 |
Reddy Us Therapeutics Inc. |
Postupci i sastavi novih triazin jedinjenja
|
|
US7163943B2
(en)
|
2001-09-21 |
2007-01-16 |
Reddy Us Therapeutics, Inc. |
Methods and compositions of novel triazine compounds
|
|
US7132423B2
(en)
|
2001-09-21 |
2006-11-07 |
Reddy Us Therapeutics, Inc. |
Methods and compositions of novel triazine compounds
|
|
US7169785B2
(en)
|
2001-09-21 |
2007-01-30 |
Reddy Us Therapeutics, Inc. |
Methods and compositions of novel triazine compounds
|
|
WO2003032903A2
(en)
*
|
2001-10-12 |
2003-04-24 |
New York University |
Trisubstituted triazines compounds with antitubulin activity
|
|
MXPA04004178A
(es)
*
|
2001-11-01 |
2004-09-06 |
Janssen Pharmaceutica Nv |
Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta.
|
|
CA2468349A1
(en)
*
|
2001-11-30 |
2003-06-12 |
Synta Pharmaceuticals Corporation |
Pyrimidine compounds
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0205688D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
|
US7442697B2
(en)
|
2002-03-09 |
2008-10-28 |
Astrazeneca Ab |
4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
|
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
|
KR100516434B1
(ko)
|
2002-04-04 |
2005-09-22 |
(주) 비엔씨바이오팜 |
6-(4-치환된-아닐리노)피리미딘 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
|
|
US20040014744A1
(en)
*
|
2002-04-05 |
2004-01-22 |
Fortuna Haviv |
Substituted pyridines having antiangiogenic activity
|
|
MY141867A
(en)
*
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
|
AU2003245669A1
(en)
*
|
2002-06-21 |
2004-01-06 |
Cellular Genomics, Inc. |
Certain aromatic monocycles as kinase modulators
|
|
US7015227B2
(en)
|
2002-06-21 |
2006-03-21 |
Cgi Pharmaceuticals, Inc. |
Certain amino-substituted monocycles as kinase modulators
|
|
DE60310730T2
(de)
|
2002-07-09 |
2007-05-16 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
|
|
EP2316459B1
(en)
*
|
2002-07-29 |
2013-11-06 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases
|
|
RU2376992C2
(ru)
*
|
2002-07-29 |
2009-12-27 |
Райджел Фармасьютикалз, Инк. |
Способы лечения или профилактики аутоиммунных заболеваний с помощью соединений 2,4-пиримидиндиамина
|
|
KR101297924B1
(ko)
*
|
2002-07-29 |
2013-08-20 |
리겔 파마슈티칼스, 인크. |
2,4-피리미딘디아민 화합물을 이용한 자가면역질환의 치료및 예방 방법
|
|
ES2445208T3
(es)
*
|
2002-07-29 |
2014-02-28 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
|
|
WO2004013145A1
(en)
*
|
2002-08-02 |
2004-02-12 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
|
AU2003272740A1
(en)
*
|
2002-10-01 |
2004-04-23 |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
|
|
CA2518407A1
(en)
*
|
2003-03-12 |
2004-09-23 |
Samaritan Pharmaceuticals, Inc. |
Animal model simulating neurologic disease
|
|
JP2006521398A
(ja)
|
2003-03-28 |
2006-09-21 |
サイオス・インコーポレーテツド |
ＴＧＦβの二−環式ピリミジン阻害剤
|
|
US20050014753A1
(en)
*
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
|
BRPI0413018B8
(pt)
|
2003-07-30 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, e, uso de um composto
|
|
GB0323137D0
(en)
|
2003-10-03 |
2003-11-05 |
Chang Lisa C W |
2,4,6- Trisubstituted pyrimidines and their different uses
|
|
WO2005040098A1
(en)
|
2003-10-21 |
2005-05-06 |
Warner-Lambert Company Llc |
Polymorphic form of n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
|
|
ES2501169T3
(es)
*
|
2003-11-24 |
2014-10-01 |
Prometic Biosciences Inc. |
Dímeros de triazina para el tratamiento de enfermedades autoinmunitarias
|
|
JP2007512275A
(ja)
|
2003-11-24 |
2007-05-17 |
エフ．ホフマン−ラ ロシュ アーゲー |
ピラゾリルおよびイミダゾリルピリミジン
|
|
WO2005054239A1
(en)
*
|
2003-12-05 |
2005-06-16 |
Bayer Healthcare Ag |
2-aminopyrimidine derivatives
|
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
|
JP2007522233A
(ja)
*
|
2004-02-11 |
2007-08-09 |
アムジエン・インコーポレーテツド |
バニロイド受容体リガンド及び治療におけるそれらの使用
|
|
US7335770B2
(en)
|
2004-03-24 |
2008-02-26 |
Reddy U5 Therapeutics, Inc. |
Triazine compounds and their analogs, compositions, and methods
|
|
TWI372624B
(en)
*
|
2004-03-30 |
2012-09-21 |
Vertex Pharma |
Azaindoles useful as inhibitors of jak and other protein kinases
|
|
US7459562B2
(en)
|
2004-04-23 |
2008-12-02 |
Bristol-Myers Squibb Company |
Monocyclic heterocycles as kinase inhibitors
|
|
JP4560329B2
(ja)
*
|
2004-05-07 |
2010-10-13 |
全薬工業株式会社 |
５−アミノピリミジン化合物
|
|
EP1763526B1
(en)
*
|
2004-06-28 |
2009-06-24 |
Bayer Schering Pharma AG |
4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
|
|
US7504521B2
(en)
|
2004-08-05 |
2009-03-17 |
Bristol-Myers Squibb Co. |
Methods for the preparation of pyrrolotriazine compounds
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
US7148348B2
(en)
|
2004-08-12 |
2006-12-12 |
Bristol-Myers Squibb Company |
Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
|
|
EP1789413A1
(en)
|
2004-09-13 |
2007-05-30 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
|
US7829712B2
(en)
|
2004-09-20 |
2010-11-09 |
Xenon Pharmaceuticals Inc. |
Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
|
|
EP2289510A1
(en)
|
2004-09-20 |
2011-03-02 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
|
|
AU2005286648A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
|
|
AR051091A1
(es)
|
2004-09-20 |
2006-12-20 |
Xenon Pharmaceuticals Inc |
Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
|
|
CA2580762A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as therapeutic agents
|
|
EP1807085B1
(en)
|
2004-09-20 |
2013-08-21 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
|
CA2580857A1
(en)
|
2004-09-20 |
2006-09-28 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
|
WO2006035061A1
(en)
|
2004-09-30 |
2006-04-06 |
Tibotec Pharmaceuticals Ltd. |
Hcv inhibiting bi-cyclic pyrimidines
|
|
PE20060608A1
(es)
|
2004-10-13 |
2006-08-22 |
Wyeth Corp |
Analogos de 17-hidroxiwortmanina como inhibidores de pi3k
|
|
US7662837B2
(en)
|
2004-10-22 |
2010-02-16 |
Janssen Pharmaceutica N.V. |
Inhibitors of c-fms kinase
|
|
US7645755B2
(en)
|
2004-10-22 |
2010-01-12 |
Janssen Pharmaceutical N.V. |
Inhibitors of c-fms kinase
|
|
ES2611604T3
(es)
*
|
2004-10-22 |
2017-05-09 |
Janssen Pharmaceutica Nv |
Inhibidores de la c fms quinasa
|
|
EP1814878B1
(en)
|
2004-11-24 |
2012-01-04 |
Rigel Pharmaceuticals, Inc. |
Spiro-2, 4-pyrimidinediamine compounds and their uses
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
DE602006010979D1
(de)
|
2005-01-19 |
2010-01-21 |
Rigel Pharmaceuticals Inc |
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
|
DK1846394T3
(da)
|
2005-02-04 |
2012-01-16 |
Astrazeneca Ab |
Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer
|
|
PT1853588E
(pt)
|
2005-02-16 |
2008-08-25 |
Astrazeneca Ab |
Compostos químicos
|
|
US20060281763A1
(en)
*
|
2005-03-25 |
2006-12-14 |
Axon Jonathan R |
Carboxamide inhibitors of TGFbeta
|
|
BRPI0609650A2
(pt)
|
2005-03-25 |
2010-04-20 |
Tibotec Pharm Ltd |
inibidores heterobicìlicos de hvc
|
|
AR056347A1
(es)
|
2005-05-12 |
2007-10-03 |
Tibotec Pharm Ltd |
Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
|
|
EP1899323A2
(en)
|
2005-05-16 |
2008-03-19 |
AstraZeneca AB |
Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
|
|
AU2006343359A1
(en)
|
2005-06-03 |
2007-11-15 |
Xenon Pharmaceuticals Inc. |
Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
WO2006133426A2
(en)
|
2005-06-08 |
2006-12-14 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
|
US8193206B2
(en)
|
2005-06-14 |
2012-06-05 |
Taigen Biotechnology Co., Ltd. |
Pyrimidine compounds
|
|
JP5118029B2
(ja)
*
|
2005-06-14 |
2013-01-16 |
タイゲン バイオテクノロジー カンパニー，リミテッド |
ピリミジン化合物
|
|
US7592451B2
(en)
|
2005-06-23 |
2009-09-22 |
New York University |
Treatment for diabetes and obesity as well as method of screening compounds useful for such treatments
|
|
US20090306038A1
(en)
*
|
2005-09-13 |
2009-12-10 |
Carceller Gonzalez Elena |
2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity
|
|
WO2007036732A1
(en)
|
2005-09-30 |
2007-04-05 |
Astrazeneca Ab |
Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
|
|
WO2007049041A1
(en)
|
2005-10-28 |
2007-05-03 |
Astrazeneca Ab |
4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
|
|
EP1954277B1
(en)
|
2005-11-03 |
2017-01-18 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
|
CA2629781A1
(en)
*
|
2005-11-16 |
2007-05-24 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
|
EA200801432A1
(ru)
*
|
2005-12-01 |
2008-12-30 |
Басф Се |
Способ получения сульфонамидов
|
|
US7713987B2
(en)
|
2005-12-06 |
2010-05-11 |
Rigel Pharmaceuticals, Inc. |
Pyrimidine-2,4-diamines and their uses
|
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
|
CN102532133A
(zh)
|
2006-01-17 |
2012-07-04 |
沃泰克斯药物股份有限公司 |
适用作詹纳斯激酶抑制剂的吖吲哚类
|
|
NZ572073A
(en)
|
2006-04-20 |
2011-09-30 |
Janssen Pharmaceutica Nv |
Heterocyclic compounds as inhibitors of c-fms kinase
|
|
BRPI0710548B8
(pt)
|
2006-04-20 |
2021-05-25 |
Janssen Pharmaceutica Nv |
inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica
|
|
EP2021329B1
(en)
|
2006-04-20 |
2016-04-13 |
Janssen Pharmaceutica N.V. |
Inhibitors of c-fms kinase
|
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
|
BRPI0714409A2
(pt)
*
|
2006-07-14 |
2013-03-12 |
Novartis Ag |
derivados de pirimidina como inibidores de alk-5
|
|
EP2046763A2
(en)
|
2006-07-31 |
2009-04-15 |
Praecis Pharmaceuticals Incorporated |
Aurora kinase inhibitors from an encoded small molecule library
|
|
JP2009545598A
(ja)
*
|
2006-08-01 |
2009-12-24 |
プリーシス・ファーマシューティカルズ・インコーポレイテッド |
Ｐ３８キナーゼ阻害剤
|
|
CA2665438C
(en)
|
2006-10-04 |
2014-12-02 |
Tibotec Pharmaceuticals Ltd. |
Carboxamide 4-[(4-pyridyl)amino]pyrimidines useful as hcv inhibitors
|
|
US8093246B2
(en)
|
2006-12-14 |
2012-01-10 |
Lexicon Pharmaceuticals, Inc. |
O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
|
|
CL2008000467A1
(es)
|
2007-02-14 |
2008-08-22 |
Janssen Pharmaceutica Nv |
Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
|
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
|
WO2009035671A1
(en)
*
|
2007-09-12 |
2009-03-19 |
Janssen Pharmaceutica N.V. |
Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine h4 receptor
|
|
AU2008305294B2
(en)
|
2007-09-21 |
2012-11-29 |
Array Biopharma Inc. |
Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
|
|
CN101821233B
(zh)
|
2007-10-12 |
2016-06-29 |
巴斯夫欧洲公司 |
生产磺酸二酰胺的方法
|
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
|
CN101903372B
(zh)
|
2007-12-21 |
2014-06-18 |
弗·哈夫曼-拉罗切有限公司 |
作为食欲肽受体拮抗剂的杂芳基衍生物
|
|
ES2375919T3
(es)
|
2008-01-11 |
2012-03-07 |
F. Hoffmann-La Roche Ag |
Moduladores de beta-amiloide.
|
|
MX2010008700A
(es)
|
2008-02-22 |
2010-08-30 |
Hoffmann La Roche |
Moduladores de beta-amiloide.
|
|
AU2008355098B2
(en)
*
|
2008-04-21 |
2012-11-15 |
Gpcr Therapeutics, Inc |
Heterocyclic compounds
|
|
BRPI0915720A2
(pt)
|
2008-06-12 |
2015-08-04 |
Janssen Pharmaceutica Nv |
Moduladores de diaminopiridina, pirimidina, e piridazina do receptor de histamina h4
|
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
TWI546290B
(zh)
|
2008-06-27 |
2016-08-21 |
賽基艾維洛米斯研究股份有限公司 |
雜芳基化合物及其用途
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
WO2010026096A1
(de)
|
2008-09-02 |
2010-03-11 |
Boehringer Ingelheim International Gmbh |
7-(piperazin-1-ylmethyl)-1h-indol-2-carbonsäure (phenyl) -amidderivate und verwandte verbindungen als p38 map-kinase-inhibitoren zur behandlung von atemwegserkrankungen
|
|
AU2009289378A1
(en)
|
2008-09-02 |
2010-03-11 |
Boehringer Ingelheim International Gmbh |
Novel benzamides, production thereof, and use thereof as medicaments
|
|
ES2429517T3
(es)
|
2008-10-09 |
2013-11-15 |
F. Hoffmann-La Roche Ag |
Moduladores para la beta amiloide
|
|
CN102209537A
(zh)
|
2008-11-10 |
2011-10-05 |
弗·哈夫曼-拉罗切有限公司 |
杂环γ分泌酶调节剂
|
|
WO2010056847A2
(en)
|
2008-11-13 |
2010-05-20 |
Taigen Biotechnology Co., Ltd. |
Lyophilization formulation
|
|
WO2010114900A1
(en)
|
2009-03-31 |
2010-10-07 |
Arqule, Inc. |
Substituted indolo-piperidine compounds
|
|
KR101705158B1
(ko)
|
2009-05-05 |
2017-02-09 |
다나-파버 캔서 인스티튜트 인크. |
Ｅｇｆｒ 억제제 및 질환 치료방법
|
|
AU2010259023A1
(en)
*
|
2009-06-08 |
2012-01-12 |
Nantbioscience, Inc. |
Triazine derivatives and their therapeutical applications
|
|
WO2010144394A1
(en)
*
|
2009-06-09 |
2010-12-16 |
Abraxis Bioscience, Llc |
Benzyl substituted triazine derivatives and their therapeutical applications
|
|
RS57869B1
(sr)
|
2009-06-17 |
2018-12-31 |
Vertex Pharma |
Inhibitori replikacije virusa gripa
|
|
US8486967B2
(en)
|
2010-02-17 |
2013-07-16 |
Hoffmann-La Roche Inc. |
Heteroaryl substituted piperidines
|
|
TW201144310A
(en)
*
|
2010-04-28 |
2011-12-16 |
Daiichi Sankyo Co Ltd |
[5,6] heterocyclic compound
|
|
TWI513694B
(zh)
*
|
2010-05-11 |
2015-12-21 |
Amgen Inc |
抑制間變性淋巴瘤激酶的嘧啶化合物
|
|
CN105566229A
(zh)
|
2010-08-10 |
2016-05-11 |
西建阿维拉米斯研究公司 |
Btk抑制剂的苯磺酸盐及其用途和制备方法
|
|
MX382354B
(es)
|
2010-11-01 |
2025-03-13 |
Celgene Car Llc |
Compuestos heterocíclicos y usos de los mismos.
|
|
EP2635285B1
(en)
|
2010-11-01 |
2017-05-03 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
JP5957003B2
(ja)
|
2010-11-10 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ， インコーポレイテッド |
変異体選択的ｅｇｆｒ阻害剤およびその使用
|
|
US20120295911A1
(en)
|
2010-11-29 |
2012-11-22 |
Galleon Pharmaceuticals, Inc. |
Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
|
|
AU2011336764B2
(en)
|
2010-11-29 |
2017-02-23 |
Galleon Pharmaceuticals, Inc. |
Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
|
|
AU2011343642A1
(en)
|
2010-12-16 |
2013-05-02 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of influenza viruses replication
|
|
ES2608967T3
(es)
*
|
2011-03-28 |
2017-04-17 |
Mei Pharma, Inc. |
(Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
|
|
CN102827073A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
|
UA118010C2
(uk)
|
2011-08-01 |
2018-11-12 |
Вертекс Фармасьютікалз Інкорпорейтед |
Інгібітори реплікації вірусів грипу
|
|
AR088570A1
(es)
|
2011-10-28 |
2014-06-18 |
Celgene Avilomics Res Inc |
Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
|
|
FR2983859B1
(fr)
|
2011-12-12 |
2014-01-17 |
Sanofi Sa |
Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
|
|
US9474779B2
(en)
|
2012-01-19 |
2016-10-25 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compositions and their methods of use
|
|
PL2825042T3
(pl)
|
2012-03-15 |
2019-02-28 |
Celgene Car Llc |
Sole inhibitora kinazy receptora czynnika wzrostu naskórka
|
|
KR102081042B1
(ko)
|
2012-03-15 |
2020-02-26 |
셀젠 카르 엘엘씨 |
상피 성장 인자 수용체 키나제 억제제의 고체 형태
|
|
WO2013138793A2
(en)
*
|
2012-03-16 |
2013-09-19 |
Maraxi, Inc. |
Affinity reagants for protein purification
|
|
JP6290884B2
(ja)
|
2012-08-07 |
2018-03-07 |
ヤンセン ファーマシューティカ エヌ．ベー． |
ｃ−ＦＭＳキナーゼ阻害剤の調製プロセス
|
|
IN2015DN00659A
(https=)
|
2012-08-07 |
2015-06-26 |
Janssen Pharmaceutica Nv |
|
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
EP2948434B1
(en)
*
|
2013-01-25 |
2017-03-01 |
Bristol-Myers Squibb Company |
Squaric derivatives for the treatment of hepatitis c
|
|
AU2014214846A1
(en)
|
2013-02-08 |
2015-07-23 |
Celgene Avilomics Research, Inc. |
ERK inhibitors and uses thereof
|
|
JP2016515105A
(ja)
*
|
2013-03-07 |
2016-05-26 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｃ型肝炎の処置のためのピリミジン化合物
|
|
US9579324B2
(en)
|
2013-07-11 |
2017-02-28 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
|
WO2015003360A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
WO2015003355A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
CN105593215B
(zh)
|
2013-07-11 |
2019-01-15 |
安吉奥斯医药品有限公司 |
用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
|
|
US20150031627A1
(en)
|
2013-07-25 |
2015-01-29 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
|
EP3055301B1
(en)
*
|
2013-10-07 |
2019-11-20 |
Kadmon Corporation, LLC |
(2-(5-isoindolin-2-yl)pyrimidin-4-yl)-amine derivatives as rho kinase inhibitors for treating autoimmune diseases
|
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
GB201403093D0
(en)
|
2014-02-21 |
2014-04-09 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
KR20240010105A
(ko)
|
2014-03-14 |
2024-01-23 |
아지오스 파마슈티컬스 아이엔씨. |
치료적으로 활성인 화합물의 약제학적 조성물
|
|
HRP20220522T1
(hr)
|
2014-08-04 |
2022-06-10 |
Nuevolution A/S |
Proizvoljno kondenzirani heterociklil-supstituirani derivati pirimidina koji su korisni za liječenje upalnih, metaboličkih, onkoloških i autoimunih bolesti
|
|
US10005760B2
(en)
|
2014-08-13 |
2018-06-26 |
Celgene Car Llc |
Forms and compositions of an ERK inhibitor
|
|
JP6704416B2
(ja)
|
2015-05-13 |
2020-06-03 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
インフルエンザウイルスの複製の阻害剤を調製する方法
|
|
JP6857617B2
(ja)
|
2015-05-13 |
2021-04-14 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
インフルエンザウイルスの複製の阻害剤
|
|
PT3362066T
(pt)
|
2015-10-15 |
2021-11-16 |
Celgene Corp |
Terapia de combinação para tratar malignidades
|
|
SG11201803088PA
(en)
|
2015-10-15 |
2018-05-30 |
Agios Pharmaceuticals Inc |
Combination therapy for treating malignancies
|
|
CN105384702B
(zh)
*
|
2015-12-11 |
2018-04-10 |
浙江大学 |
三取代均三嗪类化合物及其制备方法
|
|
CN105399695B
(zh)
*
|
2015-12-11 |
2019-04-19 |
浙江大学 |
三嗪类化合物及其制备方法和用途
|
|
AU2016379444B2
(en)
|
2015-12-24 |
2021-04-29 |
The Regents Of The University Of California |
CFTR regulators and methods of use thereof
|
|
WO2017151409A1
(en)
|
2016-02-29 |
2017-09-08 |
University Of Florida Research Foundation, Incorporated |
Chemotherapeutic methods
|
|
JP2020531511A
(ja)
|
2017-08-24 |
2020-11-05 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
眼球用医薬組成物
|
|
GB201715194D0
(en)
|
2017-09-20 |
2017-11-01 |
Carrick Therapeutics Ltd |
Compounds and their therapeutic use
|
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
|
WO2019071147A1
(en)
|
2017-10-05 |
2019-04-11 |
Fulcrum Therapeutics, Inc. |
INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
|
|
US10980788B2
(en)
|
2018-06-08 |
2021-04-20 |
Agios Pharmaceuticals, Inc. |
Therapy for treating malignancies
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
|
WO2020180959A1
(en)
|
2019-03-05 |
2020-09-10 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
|
TW202115024A
(zh)
|
2019-08-14 |
2021-04-16 |
美商英塞特公司 |
作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
|
|
AU2020364007A1
(en)
|
2019-10-11 |
2022-04-28 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
JP7390487B2
(ja)
*
|
2019-12-03 |
2023-12-01 |
サムジン ファーマシューティカル カンパニー，リミテッド |
焦点接着キナーゼ阻害剤としての新規なアダマンタン誘導体
|
|
GB201918541D0
(en)
|
2019-12-16 |
2020-01-29 |
Carrick Therapeutics Ltd |
Therapeutic compounds and their use
|
|
MX2022007265A
(es)
|
2019-12-20 |
2022-09-09 |
Nuevolution As |
Compuestos activos frente a receptores nucleares.
|
|
US11685727B2
(en)
|
2019-12-20 |
2023-06-27 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
|
EP4126874A1
(en)
|
2020-03-31 |
2023-02-08 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
|
CA3174176A1
(en)
|
2020-03-31 |
2021-10-07 |
Sanne Schroder Glad |
Compounds active towards nuclear receptors
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|